ZyVersa Therapeutics receives Nasdaq delisting notice; trading suspended July 17

ZyVersa Therapeutics, Inc.

Nasdaq Hearings Panel denied request to continue listing on the Nasdaq Capital Market.
Common stock trading suspended at open on July 17, 2025; plans to trade on OTC Pink Limited Market.
Delisting stems from non-compliance with minimum bid price requirement under Rule 5550(a)(2).
Company may request review by Nasdaq Council within 15 days of Panel decision.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.